The KSR1 Knockout Jurkat Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population for functional analysis of the scaffold protein KSR1 in a human T-lymphocyte background. This product, generated via CRISPR/Cas9-mediated gene disruption, offers a heterogeneous loss-of-function model that preserves the biological variability inherent in polyclonal populations while enabling robust interrogation of KSR1-dependent signaling networks.
The host cell line, Jurkat, is a widely employed model of human acute T-cell leukemia, originally derived from the peripheral blood of a 14-year-old male with T-cell leukemia. Jurkat cells exhibit hallmark characteristics of T-lymphocyte biology and are extensively used in studies of T-cell receptor (TCR) signaling, apoptosis, and leukemogenesis, making them a physiologically relevant context for assessing KSR1 function.
KSR1 functions as a molecular scaffold facilitating signal transduction through the Ras/MAPK pathway. Upon growth factor stimulation, KSR1 translocates to the plasma membrane and scaffolds the kinases RAF1 (or BRAF), MEK1/2 (MAP2K1/MAP2K2), and ERK1/2 (MAPK1/MAPK3), thereby promoting efficient ERK phosphorylation. This activation is downstream of Ras GTPases (HRAS, KRAS, NRAS) and upstream of transcription factors such as ELK1, FOS, and JUN. KSR1 interacts directly with 14-3-3 proteins (YWHAB, YWHAE) and the phosphatase PPP2CA, modulating its localization and activity. Key upstream regulators include TCR activation, epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and phorbol esters.
In the Jurkat leukemia context, KSR1 knockout disrupts MAPK-dependent signals critical for proliferation and survival. The polyclonal knockout population allows dissection of KSR1??s role in TCR-mediated ERK activation and its contribution to leukemic cell growth, while avoiding clonal artifacts inherent in single-cell-derived lines. This model is particularly suited for examining pathway redundancy and feedback mechanisms in a near-physiological heterogeneous cell pool.
Researchers can employ this knockout model to investigate MAPK/ERK signaling in cancer, T-cell receptor signal transduction, leukemia cell proliferation, and mechanisms of drug resistance to Raf-MEK-ERK pathway inhibitors. Representative experiments include Western blotting for phospho-ERK, co-immunoprecipitation of KSR1-Raf complexes, flow cytometric assessment of phospho-ERK, RT-qPCR for FOS or JUN transcript levels, proliferation assays, and drug sensitivity testing with MEK inhibitors. For further technical information, please contact Ascent Research.
